Accounting for the differences and understanding the appropriate way to model the marketplace for biosimilars, as opposed to generics, may have significant consequences for economic analyses in the context of litigation. In this article, we identify some of those differences and their implications.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...